Sign in

CIK 0001228627 · Non-accelerated filer<br>Smaller reporting company

Opus Genetics, Inc.

Sign in to watch
Ticker
IRD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
113516358
Phone
(984) 884-6030
Business address
8 DAVIS DRIVE, SUITE 220, DURHAM, NC, 27713
Former names
Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., CORPORATE ROAD SHOW DOT COM INC, FERRARO FRANK
  1. 4 Grant or award President acquired 332,800 shares (grant or award)
  2. 4 Shares withheld for taxes Chief Executive Officer gave up 37,050 shares (to pay taxes)
  3. 3 Insider Initial Statement of Ownership
  4. 4 Derivatives Options or other derivatives
  5. 4 Grant or award Director acquired 100,000 shares (grant or award)
  6. 3 Insider Initial Statement of Ownership
  7. 3 Insider Initial Statement of Ownership
  8. 3 Insider Initial Statement of Ownership
  9. 4 Grant or award Director acquired 41,143 shares (grant or award)
  10. 4 Grant or award Director acquired 41,143 shares (grant or award)
  11. 4 Grant or award Director acquired 41,143 shares (grant or award)
  12. 4 Grant or award Director acquired 41,143 shares (grant or award)
  13. 4 Grant or award Director acquired 41,143 shares (grant or award)
  14. 4 Grant or award Director acquired 41,143 shares (grant or award)
  15. 4 Open-market buy Chief Scientific & Dev. Ofc. bought 3,500 shares at $1.77 ($6,178)
  16. 4 Open-market buy Chief Executive Officer bought 5,000 shares at $1.75 ($8,773)
  17. 4 Grant or award Director acquired 32,000 shares (grant or award)
  18. 4 Open-market buy Chief Operating Officer bought 2,000 shares at $2.05 ($4,100)
  19. 4 Open-market buy Chief Financial Officer bought 10,000 shares at $2.10 ($21,000)
  20. 4 Open-market buy Chief Executive Officer bought 25,000 shares at $1.96 ($49,050)

Page 5 of 21 · 403 filings